as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,456.2
Change
+50.2 (3.57%)
Open
₹1,398.3
Prev. Close
₹1,406.0
Day High
₹1,473.9
Day Low
₹1,381.0
Volume Analysis
Traded
8,013
Delivered
3,833
Delivery %
47.83%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Promoter holding is rising
- •Strong operating margin (35.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (25.5%)
- •Strong 3-year revenue growth (31.8%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,585.96 | ₹1,529.93 | ₹1,493.06 | ₹1,437.03 | ₹1,400.16 | ₹1,344.13 | ₹1,307.26 |
| Fibonacci | ₹1,529.93 | ₹1,494.44 | ₹1,472.52 | ₹1,437.03 | ₹1,401.54 | ₹1,379.62 | ₹1,344.13 |
| Camarilla | ₹1,481.75 | ₹1,473.23 | ₹1,464.72 | ₹1,437.03 | ₹1,447.68 | ₹1,439.17 | ₹1,430.65 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+3.44%
1 Month
+1.04%
3 Months
+24.59%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹761.99
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.13%
Net margin 36.6% × asset turnover 0.38x × equity multiplier 1.16x
Company Overview
Sector
Healthcare
Market Cap
₹1,207 Cr
P/E (TTM)
21.7
ROE
19.8%
Book Value
₹378.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
3b Blackbio Dx Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Liquidity (29/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; strong operating margin (35.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company is expected to give good quarter
- +Company's median sales growth is 21.9% of last 10 years
- −Earnings include an other income of Rs.27.4 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Special Window for Re-lodgement of Transfer Requests of Physical shares
3B BlackBio Dx met Marcellus Investment Managers on 16 Sep 2026; no UPSI shared.
3B BlackBio Dx held one-to-one investor meeting with Capri Global Holdings on 11 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 14 | 19 | 18 | 23 | 19 | 29 | 25 | 23 | 22 | 34 | 50 | 35 | 33 |
| Expenses + | 8 | 11 | 9 | 13 | 8 | 13 | 10 | 15 | 10 | 19 | 29 | 27 | 25 |
| Operating Profit | 6 | 8 | 9 | 10 | 11 | 16 | 15 | 8 | 12 | 15 | 22 | 8 | 9 |
| OPM % | 45.1% | 40.62% | 50.2% | 42.96% | 56.36% | 55.47% | 59.35% | 35.2% | 53.22% | 43.45% | 43.14% | 23.96% | 25.44% |
| Other Income + | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 5 | 4 | 6 | 6 | 10 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 |
| Profit before tax | 9 | 10 | 11 | 14 | 14 | 19 | 18 | 13 | 16 | 20 | 27 | 15 | 13 |
| Tax % | 21.55% | 26.02% | 23.68% | 35.98% | 21.31% | 22.99% | 24.17% | 35.89% | 20.3% | 23.34% | 16.39% | 33.11% | 32.07% |
| Net Profit + | 7 | 8 | 9 | 9 | 11 | 15 | 13 | 8 | 13 | 15 | 22 | 10 | 9 |
| EPS in Rs | 10 | 10 | 10 | 10 | 13 | 17 | 16 | 10 | 15 | 17 | 25 | 11 | 11 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | 142 | 153 |
| Expenses + | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 41 | 46 | 85 | 100 |
| Operating Profit | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 33 | 50 | 57 | 53 |
| OPM % | 7.0% | 9.0% | 16.0% | 23.0% | 31.0% | 32.0% | 66.0% | 46.0% | 47.0% | 44.0% | 52.0% | 40.0% | 35.0% |
| Other Income + | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 13 | 15 | 26 | 27 |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 6 |
| Profit before tax | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 44 | 64 | 77 | 74 |
| Tax % | 23.0% | 23.0% | 19.0% | 24.0% | 25.0% | 23.0% | 25.0% | 26.0% | 27.0% | 28.0% | 25.0% | 22.0% | — |
| Net Profit + | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | 60 | 56 |
| EPS in Rs | 0 | 1 | 2 | 5 | 8 | 10 | 152 | 43 | 35 | 37 | 56 | 68 | 65 |
| Dividend Payout % | 0.0% | 0.0% | 17.0% | 9.0% | 6.0% | 7.0% | 6.0% | 24.0% | 8.0% | 8.0% | 7.0% | 7.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 316 |
| Borrowings + | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 0 | 3 |
| Other Liabilities + | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 19 | 24 | 27 | 51 |
| Total Liabilities | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
| Fixed Assets + | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 7 | 7 | 28 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 117 | 156 | 158 |
| Other Assets + | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 123 | 132 | 193 |
| Total Assets | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 248 | 296 | 378 |
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 | 9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | 52 |
| Cash from Investing Activity + | 0 | 0 | 0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -33 | -24 |
| Cash from Financing Activity + | 0 | -1 | 0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | -1 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 7 | 28 |
| CFO/OP | 23 | 69 | 36 | 52 | 71 | 101 | 90 | 129 | 100 | 115 | 116 | 121 |
| Free Cash Flow | 0 | 1 | 0 | 1 | 3 | 6 | 96 | 35 | 18 | 26 | 42 | 27 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 57.6% | 56.99% | 53.85% | 53.48% | 53.48% | 54.29% | 54.64% | 54.28% | 54.26% | 54.27% | 54.5% | 54.4% |
| Promoters | 38.43% | 38.43% | 41.29% | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.27% | 40.94% | 40.95% |
| FII | 3.16% | 3.38% | 2.97% | 3.28% | 3.27% | 2.68% | 2.49% | 2.7% | 2.64% | 2.57% | 2.57% | 2.5% |
| DII | 0.82% | 1.18% | 1.89% | 1.96% | 1.96% | 1.74% | 1.6% | 1.76% | 1.82% | 1.87% | 1.98% | 2.15% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| 3b Blackbio Dx Ltd. (this stock) | 1,207 | 21.7 | 3.72 | 19.8% |
| Lincoln Pharma Ltd | 1,182 | 12.2 | 1.56 | 12.3% |
| Sigachi Industries Ltd | 1,125 | 50.0 | 2.16 | 5.78% |
| Laxmi Dental Limited | 1,097 | 31.6 | 4.49 | 14.8% |
| Gpt Healthcare Limited | 1,331 | 32.0 | — | 28.5% |
| Themis Medicare Ltd. | 1,077 | 624.0 | 2.7 | 0.41% |
| Bharat Parenterals Ltd. | 1,077 | — | 3.3 | -2.54% |
Which Mutual Funds Hold 3b Blackbio Dx Ltd.?
Frequently Asked Questions about 3b Blackbio Dx Ltd.
3b Blackbio Dx Ltd. (3BBLACKBIO) closed at ₹1,456.2 on NSE on 25 September 2026, up 50.2 (3.57%) from the previous close.
3b Blackbio Dx Ltd. trades on the NSE (National Stock Exchange of India) under the symbol 3BBLACKBIO.
3b Blackbio Dx Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 21.7.
3b Blackbio Dx Ltd. has a dividend yield of 0.36%.
3b Blackbio Dx Ltd.'s 52-week high is ₹1,750.0 and its 52-week low is ₹1,084.0.
3b Blackbio Dx Ltd. has a market capitalisation of ₹1,207 crore.
3b Blackbio Dx Ltd. has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about 3b Blackbio Dx Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.